 2. A. For the dose escalation phase: Patients with histological or cytological confirmed solid tumours including sarcomas, for which there is no known curative therapy B. For the MTD expansion phase: Patients with an established diagnosis of soft tissue sarcoma in need of first line chemotherapy and with measurable disease 